STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
Key facts
- Where
- Anderlecht, Bonheiden, Bruges, Edegem, and Leuven, BelgiumSee the 5 sites
Where in Belgium
- Hôpital Universitaire de BruxellesAnderlecht, BelgiumTaking people
- Imelda ZiekenhuisBonheiden, BelgiumTaking people
- AZ Sint Lucas, BruggeBruges, BelgiumTaking people
- Universitair Ziekenhuis AntwerpenEdegem, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Trial code
- NCT07863258
- Record updated
- 7 October 2026
- Original description
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from modern systemic therapies, using the RECIST 1.1 framework as the primary benchmark.Read full original descriptionShow less
Treatment STRATification in Patients With Advanced HEPatocellular Carcinoma (STRATHEP)
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from modern systemic therapies, using the RECIST 1.1 framework as the primary benchmark.
Participants eligible for inclusion in this Study must meet all of the following criteria:; Male or female, age > 18 years; Hepatocellular carcinoma treated with systemic treatment during the disease course; Histological confirmation of HCC within one year of the start of systemic treatment OR the availability of an MRI of the liver within 6 months of the start of systemic treatment; Left-over tissue from previous diagnostic biopsy available; Ability to sign informed consent for secondary use of archival tissue and data collection for study-specific research for patients who are alive and that have not yet reached a 5-year follow-up period; Participants eligible for this Study must not meet any of the following criteria:; Hepatocellular carcinoma not treated systemically; Other malignancies of the liver, including cholangiocarcinoma.